Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

131.28 -1.45 (-1.09%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

76 77 Next >

Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial ↗

July 28, 2026

Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.

Via Benzinga

Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees ↗

July 28, 2026

VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors.

Via The Motley Fool

Topics ETFs

Global Prophylactic HIV Drug Market Growing at 7.8% CAGR Through 2034 ↗

July 27, 2026

According to a new report from Intel Market Research, the global Prophylactic HIV Drug Market was valued at USD 3.45 billion in 2025 and is projected to re

Via Talk Markets

Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors ↗

July 24, 2026

Via Chartmill

CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

July 24, 2026

From Gilead Sciences, Inc.

Via Business Wire

iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? ↗

July 23, 2026

VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield.

Via The Motley Fool

Topics ETFs

Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026? ↗

July 22, 2026

One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains.

Via The Motley Fool

Topics ETFs

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

July 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill ↗

July 21, 2026

Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.

Via Benzinga

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

July 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

July 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

3 Market-Beating Stocks with Solid Fundamentals

July 21, 2026

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...

Via StockStory

Topics Energy

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

July 20, 2026

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.19% on an annualized basis producing an average annual return of 11.43%. Currently, Gilead Sciences has a market...

Via Benzinga

IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? ↗

July 19, 2026

BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.

Via The Motley Fool

Topics ETFs

IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? ↗

July 18, 2026

IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.

Via The Motley Fool

Topics ETFs

Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move. ↗

July 17, 2026

Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?

Via Investor's Business Daily

Topics Intellectual Property

Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings ↗

July 16, 2026

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as critics warn the wagers invite insider trading.

Via Benzinga

Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026? ↗

July 14, 2026

RSPH offers 60 diversified holdings with lower volatility, while BBH concentrates on 25 biotech leaders with stronger recent returns.

Via The Motley Fool

Topics ETFs

Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1

July 13, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong. ↗

July 12, 2026

Gilead's expansion beyond HIV therapies will surprise many investors.

Via The Motley Fool

Topics Intellectual Property

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? ↗

July 11, 2026

IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.

Via The Motley Fool

Topics ETFs

Which is the Better Choice for Healthcare Investors? IYH or BBH? ↗

July 11, 2026

BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield.

Via The Motley Fool

Topics ETFs

What's going on in today's session: S&P500 movers ↗

July 10, 2026

Via Chartmill

2 Recession-Resistant Dividend Stocks to Buy and Hold ↗

July 10, 2026

You don't need to predict a recession to prepare your portfolio. These two stocks can help.

Via The Motley Fool

Topics Economy

IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? ↗

July 10, 2026

Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH? ↗

July 08, 2026

IBBQ offers lower costs and broader diversification, while XPH delivered stronger 1-year returns with less volatility.

Via The Motley Fool

Topics ETFs

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners? ↗

July 08, 2026

Broader diversification and lower volatility set these healthcare ETFs apart, with each fund targeting a distinct segment of the industry.

Via The Motley Fool

Topics ETFs

Stay informed with the top movers within the S&P500 index on Tuesday. ↗

July 07, 2026

Via Chartmill

Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says ↗

July 06, 2026

HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV & oncology potential.

Via Benzinga

MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition

July 06, 2026

Via Investor Brand Network

< Previous 1 2 3 4 5 6 7 8 9

...

76 77 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.